Zárate A, Islas S, Saucedo R

Language: Spanish
References: 9
Page: 5-7
PDF size: 203.16 Kb.

ABSTRACT

The management of type 2 diabetes is still a challenge and a conundrum for treatment intensity and choice of pharmaceutical agent. There is also uncertainty about possible cardiovascular adverse effects.

REFERENCES

1. Lebovitz HE. Keeping tabs on oral agents. Diabetes Care. 1988;11: 598-9.

2. Hemmingsen B, Lund SS, Wetterslev J, Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol. 2009;161:1-9.

3. Zárate A, Basurto L, Saucedo R, Hernández-Valencia M. Guía para seleccionar el tratamiento farmacológico en diabetes 2. Rev Med Inst Mex Seguro Soc. 2010;48:293-6.

4. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364: 818-28.

5. European Association for the Study of Diabetes Congress 2013 Barcelona. [Internet] Disponible en: www.diabetes-symposium.org.

6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.

7. Home PD, Pocock SJ, Beck-Nielsen H. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet. 2009;373:2125-35.

8. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med. 2013; 369:1285-7.

9. Scirica BM, Bhatt DL, Braunwald E, Steg G, Davidson J, Hirshberg B. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.